

## DONALD L. REYNOLDS, Ph.D.

## MANUSCRIPTS AND BOOK CHAPTERS

RECENT ADVANCES IN ANALYTICAL CHEMISTRY by Lawrence A. Pachla, Donald L. Reynolds and D. Scott Wright in Pharmacokinetics: Regulatory - Industrial - Academic Perspectives, Peter G. Welling and Francis L. S. Tse, Editors, Marcel Dekker, Inc., New York, New York, 1988, pp. 57-96.

COMPARISON OF BIOLOGICAL AND CHEMICAL ASSAYS FOR THE QUANTITATION OF RIFAPENTINE IN HUMAN PLASMA, Michael T. Kenny, Donald L. Reynolds, Marcia A. Brackman and Jacqueline K. Dulworth, Diagn. Microbiol. Infect. Dis., 27, 1997, pp. 107-111.

AN INVESTIGATION OF THE DOSE PROPORTIONALITY OF DEFLAZACORT PHARMACOKINETICS, Niranjan Rao, Vijay O. Bhargava, Donald L. Reynolds, Mark G. Eller and Scott J. Weir, Biopharm. Drug Disp., 17, 1996, pp. 753-760.

PHARMACOKINETICS AND PHARMACODYNAMICS OF THE MONOAMINE OXIDASE B INHIBITOR MOFEGILINE ASSESSED DURING A PHASE I DOSE TOLERANCE TRIAL, Maxine Stoltz, Donald Reynolds, Linda Elkins, Daniel Salazar and Scott Weir, Clin. Pharmacol. Ther., 58(3), 1995, pp. 342-353.

QUANTITATIVE DETERMINATION OF 21-HYDROXY-DEFLAZACORT IN HUMAN PLASMA USING GRADIENT SEMI-MICROBORE LIQUID CHROMATOGRAPHY, Donald L. Reynolds, Steve D. Burmaster and Larry S. Eichmeier, Biomed. Chromatogr., 8, 1994, pp. 230-235.

ISOMERIC SEPARATION OF BERAPROST SODIUM USING AN  $\alpha_1$ -ACID GLYCOPROTEIN COLUMN, Laurie A. Sly, Donald L. Reynolds and Thomas A. Walker, J. Chromatogr., 641, 1993, pp. 249-255.

DETERMINATION OF MDL 201,012 AT FEMTOMOLE/MILLILITRE LEVELS IN HUMAN PLASMA BY LIQUID CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION, Donald L. Reynolds, Larry S. Eichmeier and Dennis H. Giesing, Biomed. Chromatogr., 6, 1992, pp. 295-299.

LIQUID CHROMATOGRAPHIC ANALYSIS OF THE ADENOSINE AGONIST PD 117519 IN DOG PLASMA, Donald L. Reynolds and Lawrence A. Pachla, J. Pharm. Biomed. Anal., 9(4), 1991, pp. 345-349.

BIOLOGICAL SAMPLE PREPARATION AND DATA REDUCTION CONCEPTS IN PHARMACEUTICAL ANALYSIS, Elvin L. Johnson, Donald L. Reynolds, D. Scott Wright and Lawrence A. Pachla, J. Chrom. Sci., 26, 1988, pp. 372-379.

ANALYTICAL METHODS FOR MEASURING URIC ACID IN BIOLOGICAL SAMPLES AND FOOD PRODUCTS, Lawrence A. Pachla, Donald L. Reynolds, D. Scott Wright and Peter T. Kissinger, J. Assoc. Off. Anal. Chem., 70(1), 1987, pp. 1-14.

BIOANALYTIC CONSIDERATIONS FOR PHARMACOKINETIC AND BIOPHARMACEUTIC STUDIES, Lawrence A. Pachla, D. Scott Wright and Donald L. Reynolds, J. Clin. Pharmacol., 26(5), 1986, pp. 332-335.

ROBOTIC ANALYSIS OF 3,7-DIMETHOXY-4-PHENYL-N-1H-TETRAZOL-5-YL-4H-FURO-(3,2-b)-INDOLE-2-CARBOXAMIDE IN HUMAN PLASMA, Elvin L. Johnson, Lawrence A. Pachla and Donald L. Reynolds, J. Pharm. Sci., 75(10), 1986, pp. 1003-1005.

A VALIDATED LIQUID CHROMATOGRAPHIC METHOD FOR THE ANTIALLERGY AGENT CI-922 IN DOG AND RAT PLASMA, I. A. Eiseman, D. L. Reynolds, E. L. Johnson, A. C. Daftsios and L. A. Pachla, J. Pharm. Biomed. Anal., 4(4), 1986, pp. 491-496.

COMMENTS ON THE URICASE/ PEROXIDASE-PHENOL-4-AMINOANTIPYRENE REACTION, Lawrence A. Pachla, Donald L. Reynolds and D. Scott Wright, Clin. Chem., 32(1), 1986, pp. 232-233.

ANALYSIS OF 3-(2-ETHYLAMINO-PROPYL-1,2,3,4-TETRAHYDRO-5H-BENZOPYRANO(3,4C)PYRIDIN-5-ONE IN PLASMA BY HPLC COLUMN SWITCHING AFTER DERIVATIZING THE SECONDARY AMINE WITH FLUORESCIEIN-6-ISOTHIOCYANATE, Donald L. Reynolds and Lawrence A. Pachla, J. Pharm. Sci., 74(10), 1985, pp. 1091-1094.

METABOLIC DISPOSITION OF THE ANTIALLERGY COMPOUND CI-922 IN LABORATORY ANIMALS, Irene A. Eiseman, Elvin L. Johnson, Donald L. Reynolds, Lawrence A. Pachla and Peter G. Welling, The Pharmacologist, 27, 1985, p. 181.

ANALYTICAL METHODS FOR DETERMINING ASCORBIC ACID IN BIOLOGICAL SAMPLES, FOOD PRODUCTS, AND PHARMACEUTICALS, Lawrence A. Pachla, Donald L. Reynolds and Peter T. Kissinger, J. Assoc. Off. Anal. Chem., 68(1), 1985, pp. 1-12.

FACTORS AFFECTING THE RETENTION OF QUATERNARY AMMONIUM IONS IN REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, Donald L. Reynolds, Christopher M. Riley, Larry A. Sternson and A. J. Repta, J. Pharm. Biomed. Anal., 1(3), 1983, pp. 347-361.

CATION EXCHANGE CONTRIBUTION TO THE RETENTION OF SPECIFIC QUATERNARY AMMONIUM COMPOUNDS IN REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, Donald L. Reynolds, A. J. Repta and L. A. Sternson, J. Pharm. Biomed. Anal., 1(3), 1983, pp. 339-346.

PLASMA LEVELS OF 1,4-DIHYDROXY-5,8-bis[(2-[(2-HYDROXYETHYL)-AMINO]-ETHYL)-AMINO]-9,10-ANTHRACENEDIONE DIHYDROCHLORIDE (DHAD) IN HUMANS, Donald L. Reynolds, Kent K. Ulrich, Thomas F. Patton, A. J. Repta, Larry A. Sternson, Mark C. Myron and Sarah A. Taylor, Int. J. Pharm., 9, 1981, pp. 67-71.

CLINICAL ANALYSIS FOR THE ANTINEOPLASTIC AGENT 1,4-DIHYDROXY-5,8-bis[(2-[(2-HYDROXYETHYL)-AMINO]-ETHYL)-AMINO]-9,10-ANTHRACENEDIONE DIHYDROCHLORIDE (NSC 301739) IN PLASMA. APPLICATION OF TEMPERATURE CONTROL TO PROVIDE SELECTIVITY IN PAIRED-ION HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, Donald L. Reynolds, Larry A. Sternson and A. J. Repta, J. Chromatogr., 222, 1981, pp. 225-240.

**ORAL PRESENTATIONS**

LC-MS/MS Matrix Effects - Mechanisms, Sources, Evaluation and Strategies to Minimize, Donald L. Reynolds, Invited Speaker, Virginia Commonwealth University, Richmond, Virginia, January 2008.

LC-MS/MS Matrix Effects - Mechanisms, Sources, Evaluation and Strategies to Minimize, Donald L. Reynolds, Invited Speaker, Lotus Clinical Research Academy, Bangalore, India, October 2007.

LC-MS/MS Matrix Effects - Mechanisms, Sources, Evaluation and Strategies to Minimize, Donald L. Reynolds, Invited Speaker, Lotus Labs Pvt. Ltd., Bangalore, India, September 2007.

HPLC Column Switching – Introduction and Selected Applications, Donald L. Reynolds, Invited Speaker, Lotus Labs Pvt. Ltd., Bangalore, India, July 2007.

Introduction to Bioanalysis, Donald L. Reynolds, Invited Speaker, Lotus Clinical Research Academy, Bangalore, India, April, July, September and October 2007.

Approaches to Bioanalytical Method Development - Strategies and Applications, Donald L. Reynolds, Invited Speaker, Lotus Clinical Research Academy, Bangalore, India, April, July, September and October 2007.

Influence of Silanol Interactions on the Retention of Amine-Containing Analytes on Silica-Based Bonded Phases – Column Chemistry and Selection of the Right Column, Donald L. Reynolds, Invited Speaker, Lotus Clinical Research Academy, Bangalore, India, April, July, September and October 2007.

Extraction Considerations for the Development of Robust Methods, Donald L. Reynolds, Invited Speaker, Lotus Clinical Research Academy, Bangalore, India, April, July, September and October 2007.

Extraction Development - Considerations for Developing Robust Extraction Methodology, Donald L. Reynolds, Invited Speaker, Lotus Labs Pvt. Ltd., Bangalore, India, March 2007.

Influence of Silanol Interactions on the Retention of Amine-Containing Analytes on Silica-Based Bonded Phases, Donald L. Reynolds, Invited Speaker, Lotus Labs Pvt. Ltd., Bangalore, India, March 2007.

Strategy for Developing Bioanalytical Methods for Marketed Products, Donald L. Reynolds, Invited Speaker, Lotus Labs Pvt. Ltd., Bangalore, India, December 2006.

Bioanalytical Method Development - Strategies and Applications, Donald L. Reynolds, Invited Speaker, Lotus Labs Pvt. Ltd., Bangalore, India, November 2006.

Bioanalytical Case Studies, Donald L. Reynolds, Invited Speaker, Panacos Pharmaceuticals, Gaithersburg, MD, May 2004.

Bioanalytical Case Studies, Donald L. Reynolds, Invited Speaker, Ricerca Biosciences, Concord, OH, February 2004.

Design and Implementation of a Fully Tunable UV/VIS Solid-State Laser-Induced Fluorescence (LIF) Detection System for HPLC Analysis, Donald L. Reynolds, US Bioanalytics Department Seminar, Hoechst Marion Roussel, Kansas City, MO, December 1998.

Design and Implementation of a Fully Tunable UV/VIS Solid-State Laser-Induced Fluorescence (LIF) Detection System for HPLC Analysis, Donald L. Reynolds, Invited Speaker, American Association of Pharmaceutical Scientists Annual Meeting, San Francisco, CA, November 1998.

Bioanalytical Case Studies, Donald L. Reynolds, Invited Speaker, Pharmaceutical Analysis II Class, The University of Kansas, Department of Pharmaceutical Chemistry, Lawrence, KS, October 1997.

Generalized Strategy for Developing Solid Phase Extraction Methods, Donald L. Reynolds, Invited Speaker, The Strategic Method Development Workshop, Marion Merrell Dow, Inc., Kansas City, MO, December 1994.

The Isomeric Separation of Beraprost Sodium Using an  $\alpha$ -1-Acid Glycoprotein Column, T. A. Walker, L. A. Sly and D. L. Reynolds, 4<sup>th</sup> International Symposium on Chiral Discrimination, Montreal, Canada, September 1993.

Development of a Chiral Separation of Beraprost Sodium Using an  $\alpha$ -1-Acid Glycoprotein Column, L. A. Sly, T. A. Walker and D. L. Reynolds, American Association of Pharmaceutical Scientists Annual Meeting, San Antonio, TX, November 1992.

Development of a Chiral Separation of Beraprost Sodium Using an  $\alpha$ -1-Acid Glycoprotein Column, L. A. Sly, T. A. Walker and D. L. Reynolds, Midwest Regional ACS Meeting, Lawrence, KS, November 1992.

Development of a Chiral Separation of Beraprost Sodium Using an  $\alpha$ -1-Acid Glycoprotein Column, L. A. Sly, T. A. Walker and D. L. Reynolds, HPLC-92, Baltimore, MD, June 1992.

A Validated Liquid Chromatographic Assay to Quantitate ML-1012 in Human Plasma at Femtomole Levels, D. L. Reynolds, L. S. Eichmeier and D. H. Giesing, Development Resources Scientific Conference, Marion Merrell Dow, Inc., Kansas City, MO, November 1991.

Strategies for Bioanalytical Methods Development, Donald L. Reynolds, Invited Speaker, Department of Pharmaceutical Chemistry Seminar, The University of Kansas, Lawrence, KS, October 1991.

A Validated Liquid Chromatographic Assay to Quantitate ML-1012 in Human Plasma at Femtomole Levels, D. L. Reynolds, L. S. Eichmeier and D. H. Giesing, 3<sup>rd</sup> International Symposium on Pharmaceutical and Biomedical Analysis, Boston, MA, April 1991.

Generalized Strategy for Developing Solid Phase Extraction Methods, Donald L. Reynolds, Invited Speaker, Kansas City Chromatography Discussion Group, Kansas City, MO, July 1990.

Validated Liquid Chromatographic Assay for the Antiallergy Agent CI-949 in Rat, Dog and Human Plasma, D. L. Reynolds, K. L. Hoffman and L. A. Pachla, American Association of Pharmaceutical Scientists Annual Meeting, Orlando, FL, October 1988.

Using Robotics in Pharmacokinetic Studies – Help or Hindrance?, Elvin L. Johnson, Keith L. Hoffman, Donald L. Reynolds and Larry A. Pachla, Eastern Analytical Symposium, New York, NY, October 1988.

Application of Robotics for the Unattended Development of Liquid-Solid Extractions and Routine Analysis of Biological Samples, D. L. Reynolds\*, E. L. Johnson, K. L. Hoffman and L. A. Pachla, \*Invited Speaker, American Midwest Regional Association of Pharmaceutical Scientists Meeting, Chicago, IL, May 1988.

Robotic Technology Applied to Pharmacokinetic/Drug Metabolism Studies, Elvin L. Johnson, Donald L. Reynolds and Lawrence A. Pachla, 10<sup>th</sup> International Symposium on Column Liquid Chromatography, San Francisco, CA, May 1986.

Use of a Chronic Intraduodenal Cannula Preparation for Two-Week Toxicity Studies in Rats, Robert Bonczyk, Michelle Roth, Barbara Windsor, Irene Eiseman, Donald Reynolds and Tsun Chang, FASEB, St. Louis, MO, April 1986.

Validated HPLC Analysis of the Antiallergy Agent CI-922, I. A. Eiseman, E. L. Johnson, L. A. Pachla, D. L. Reynolds and P. G. Welling, Academy of Pharmaceutical Sciences Annual Meeting, Minneapolis, MN, October 1985.

Analysis of the New Bronchodilator 3-[2-(Ethylamino)-propyl]-1,2,3,4-tetrahydro-5H-(1)-benzopyrano(3,4-c)pyridin-5-one (CI-923) in Plasma by Liquid Chromatography Following Derivatization with Fluorescein-6-Isothiocyanate (F6ITC), Donald L. Reynolds and Lawrence A. Pachla, Academy of Pharmaceutical Sciences Annual Meeting, Philadelphia, PA, October 1984.

The Retention Behavior of Quaternary and bis-Quaternary Ammonium Compounds in Reversed-Phase HPLC Systems, Donald L. Reynolds, A. J. Repta and L. A. Sternson, Academy of Pharmaceutical Sciences Annual Meeting, San Diego, CA, November 1982.

The Retention Behavior of Quaternary and bis-Quaternary Ammonium Compounds in Reversed-Phase HPLC Systems, D. L. Reynolds, A. J. Repta and L. A. Sternson, 6<sup>th</sup> International Symposium on Column Liquid Chromatography, Cherry Hill, NJ, June 1982.

The Effects of Temperature and Ion Pairing on the HPLC Behavior of the Antineoplastic Agent DHAD (NSC 301739), Donald L. Reynolds, L. A. Sternson and A. J. Repta, Academy of Pharmaceutical Sciences Annual Meeting, San Antonio, TX, November 1980.